Spectrum Brands Holdings Inc. (SPB - Free Report) posted better-than-expected results in third-quarter fiscal 2020. Results gained from solid demand for its products throughout the quarter. Notably, the majority of its segments delivered sturdy sales growth. However, supply-chain disruptions related to the Hardware & Home Improvement segment hurt quarterly growth to some extent.
Moving on, the company’s global productivity improvement plan savings contributed to quarterly growth. Encouragingly, this plan is anticipated to generate at least $100 million of full run-rate cost savings over the next nine to 12 months.
Despite such upsides, management withdrew the fiscal 2020 view. That said, demand remains positive for three of its four categories. Also, Spectrum Brands estimates shipments and factory output to improve in the fiscal fourth quarter.
Spectrum Brands Holdings Inc. Price, Consensus and EPS Surprise
Q3 in Detail
Adjusted earnings from continuing operations of $1.36 per share surpassed the Zacks Consensus Estimate of 96 cents. The bottom line also inched up 0.7% on the back of a fall in shares outstanding, favorable pricing and productivity, which more than offset supply-chain disruptions in the Hardware & Home Improvement segment.
Spectrum Brands’ net sales decreased 3.7% year over year to $984.3 million but exceeded the Zacks Consensus Estimate of $938 million. Excluding the negative impacts of currency and sales from buyouts, organic net sales fell 2.9% due to supply-chain disruptions in the Hardware & Home Improvement segment, which was somewhat offset by higher sales at Home & Garden, Home & Personal Care and Global Pet Care.
Moreover, its e-commerce unit continued to witness significant growth across all categories. To this end, sales in this platform rose 44% year over year, accounting for roughly 16% of net sales.
Gross profit dipped 3.4% year over year to $348.9 million. Meanwhile, gross margin expanded10 bps to 35.4%, mainly driven by favorable pricing and productivity. However, supply-chain headwinds in the Hardware & Home Improvement segment acted as a deterrent. Apart from these, SG&A expenses fell 3.4% to $225 million, while SG&A as a percentage of sales remained flat at 22.8%. This can be mainly attributable to reduced operating and restructuring costs.
Furthermore, the company reported operating income of $94.6 million, up 1.9% year over year in the reported quarter. The uptick can be attributable to reduced restructuring expenses, which were somewhat offset by supply-chain headwinds in the Hardware & Home Improvement segment.
Adjusted EBITDA from continuing operations declined 4.9% to $164.4 million in the fiscal third quarter. Further, adjusted EBITDA margin contracted 20 bps on sluggishness in the Hardware & Home Improvement segment, which was somewhat offset by solid performance in the Global Pet Care, Home & Personal Care and Home & Garden segments.
The company also noted that supply-chain disruptions affected operating income and adjusted EBITDA to the tune of more than $30 million.
Sales at the Hardware & Home Improvement segment declined 20.6% to $281.6 million mainly due to softness in the security category and supply-chain disruptions, particularly in Mexico and the Philippines, stemming from government-imposed restrictions related to COVID-19. Also, a decline in residential security due to supply-chain disruptions in Asia more than offset growth in builders’ hardware on the back of product innovation in the home center and online space. The segment’s organic sales dropped 20.4% year over year. Also, adjusted EBITDA at the segment slumped 35.6% to $43.6 million.
Sales at the Home & Personal Care segment increased 3% to $250.6 million, backed by growth at the U.S. small appliances, solid demand and sturdy online sales. This was somewhat offset by a decline in personal care due to lower inventory as a result of the COVID-19 crisis. Excluding the adverse impacts of foreign currency, organic net sales for the segment increased 6.5%. Moreover, the segment’s adjusted EBITDA of $25 million improved 37.4% on productivity improvements and higher volumes.
The Global Pet Care segment’s sales grew 8.9% year over year to $241.5 million, primarily driven by high-single-digit and double-digit growth in aquatic and companion animal categories, respectively. Also, strong e-commerce sales along with a spike in demand for aquatics and reptile kits and equipment contributed to segment growth. Excluding the adverse impacts of foreign currency and sales from acquisitions, organic sales rose 8.3%. Further, the segment’s adjusted EBITDA grew 29.7% to $50.6 million.
The Home & Garden segment’s sales rose 4% to $210.6 million mainly on higher sales in household insect controls and repellents. Also, growth in mass, home center, and online channels along with favorable weather aided segment sales. This was somewhat compensated by growth in outdoor controls. Further, the segment’s adjusted EBITDA was up 4.4% to $55.5 million in the prior-year quarter.
Spectrum Brands ended the quarter with cash and cash equivalents of $465.9 million and roughly $341 million available under its $800-million Cash Flow Revolver. As of Jun 30, 2020, the company’s outstanding debt was nearly $2,720 million. Capital expenditure came in at $12.8 million, down from $13.2 million last year. The company boasts liquidity of $800 million, which is likely to help it stay afloat amid this ongoing pandemic.
In the past three months, shares of this Zacks Rank #3 (Hold) company have gained 29.7% against the industry’s 11% decline.
Stocks to Consider
Crocs (CROX - Free Report) has a long-term earnings growth rate of 15% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Whirlpool Corporation (WHR - Free Report) has a long-term earnings growth rate of 16.7%. Currently, it carries a Zacks Rank #1.
Sony Corporation (SNE - Free Report) , also a Zacks Rank #2 (Buy) stock, has a long-term earnings growth rate of 5.8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>